This is a purely administrative clarification with no trading implications for ASBP common stock. The ASBPW warrants are now deeply out of the money with a $13,800 strike price, making them effectively worthless. Monitor for any potential delisting risk given the $8M market cap and extreme reverse splits.
Price Chart
Executive Summary
Aspire Biopharma filed an 8-K to clarify the terms of its public warrants (ASBPW) following two reverse stock splits. The warrants, originally issued with an $11.50 exercise price, now have an exercise price of $13,800 per share and require 1,200 warrants to purchase one share of common stock. This is a routine clarification with no material financial impact on the company's operations or common stock.
Key Facts
- The company filed an 8-K to clarify the terms of its public warrants (ASBPW) following two reverse stock splits.
- A 1-for-30 reverse split was effected on January 16, 2026, and a 40-1 reverse split was effected on May 11, 2026.
- As a result, the warrants now have an exercise price of $13,800 per share and a ratio of 1,200 warrants to purchase one share of common stock.
- The warrants were originally issued on February 23, 2022, in connection with the IPO of Power Up Acquisition Corp., the company's predecessor.
Financial Impact
No financial impact. The filing is a clarification of warrant terms with no new capital raised or financial obligations.
Risk Factors
- The warrants are now deeply out of the money and effectively worthless, which could lead to delisting of ASBPW.
- The company has executed two reverse splits in 2026, indicating potential Nasdaq compliance issues.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-033942 |
| Document: 0001493152-26-033942-index-headers.html | 0001493152-26-033942 |
| Document: 0001493152-26-033942-index.html | 0001493152-26-033942 |
| Document: 0001493152-26-033942.txt | 0001493152-26-033942 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 8-K/A | $8.85 | awaiting T+20 | — | $8.44 (−4.63%) |
Aug 19, 2026 9w ago | 8-K | $7.90 $9.12 | ▲ +15.44% | ▲ +17.39% | $8.44 (+6.84%) |
Aug 10, 2026 11w ago | 8-K | $7.79 $8.85 | ▲ +13.61% | ▲ +14.52% | $8.44 (+8.34%) |
Jul 20, 2026 14w ago | 8-K | $7.54 $7.64 | ▲ +1.33% | ▼ −1.24% | $8.44 (+11.94%) |
Jun 12, 2026 19w ago | 8-K | $4.96 $6.01 | ▲ +21.17% | ▲ +19.39% | $8.44 (+70.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers